01Purpose and principlesWhat the treatment does and how it fits into care.
Giving systemic therapy first creates opportunities and obligations. It may convert an inoperable tumour to operable, reduce the volume of breast or axillary surgery and show whether the chosen biological strategy is active. The cost is that untreated anatomical extent can become difficult to locate. Clips, photographs, measurements and node identity therefore belong in the plan before the first dose, along with fertility, cardiac, infection and organ-function assessment.
Regimens follow phenotype and current commissioning. Triple-negative and HER2-positive disease often benefit from preoperative therapy because pathological response carries prognostic and postoperative-treatment information. ER-positive HER2-negative tumours vary: chemotherapy may be indicated by risk, while postmenopausal endocrine therapy can shrink selected cancers when no definite chemotherapy need exists. Surgery remains necessary to establish residual disease and local control unless an exceptional specialist plan says otherwise.
Key points
- Neoadjuvant treatment is systemic therapy given before surgery to treat micrometastatic risk, improve operability or conservation and reveal in-vivo treatment response.
- Secure core histology, ER, PR and HER2, axillary assessment and appropriate clinical staging before treatment; mark the breast target and any proven node that may become occult.
- Where neoadjuvant chemotherapy is indicated for HER2-positive invasive cancer, NICE says offer it within relevant commissioning criteria; pertuzumab with trastuzumab is an option for defined high-risk disease.
- For triple-negative invasive cancer where neoadjuvant chemotherapy is indicated, NICE 2025 says offer a regimen containing platinum, taxane and anthracycline after discussing toxicity and individual circumstances.
- Postmenopausal ER-positive cancer without a definite chemotherapy indication may use neoadjuvant endocrine therapy to reduce tumour size after comparing slower response and adverse effects.
- Clinical or imaging response cannot replace surgery and pathological assessment. Residual invasive disease and baseline stage determine important postoperative escalation pathways.
02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.
Skin, chest-wall or extensive nodal involvement may prevent safe immediate surgery; systemic response can create a resectable plane and improve local control.
A unifocal tumour that is large relative to the breast may shrink enough to permit breast conservation, although original distribution still guides surgery.
Triple-negative and HER2-positive cancers may show marked pathological response, which informs prognosis and adjuvant treatment selection.
Increasing tumour, new skin involvement or new distant symptoms during treatment requires prompt reassessment of diagnosis, regimen and operability.
03Assessment before treatmentTests and checks that guide safe selection.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Core histology and simultaneous receptorsFirst step - Why
- Confirm invasive cancer and define ER, PR and HER2 before selecting systemic treatment.
- Interpretation and limitations
- Insufficient or discordant tissue must be resolved before treatment removes or alters the target. Record grade and biopsy site.
- 02
Pretreatment imaging and clip placement - Why
- Measure breast and nodal disease and preserve target location if response makes it impalpable.
- Interpretation and limitations
- Map disease with mammography and ultrasound, using selected MRI for a defined extent question. Document clips in the index lesion and relevant proven node.
- 03
Baseline toxicity assessment - Why
- Check organ function, blood count, performance, pregnancy and cardiac risk required by the intended regimen.
- Interpretation and limitations
- Abnormalities can change drug, dose or schedule and need an explicit specialist plan rather than unrecorded empiricism.
- 04
Interval response assessment - Why
- Detect response or progression early enough to alter treatment and keep surgery feasible.
- Interpretation and limitations
- Use the same measurable clinical and imaging targets. Complete imaging response is not proof that no viable tumour remains.
04Treatment approachPreparation, options, escalation and aftercare.
01Worked case: HER2-positive pathwayPrepare the target before it disappearsFirst stepA 43-year-old has a 45 mm HER2-positive invasive cancer and a clipped biopsy-proven axillary node; neoadjuvant chemotherapy is indicated.+
- 1In this illustrative case, core pathology confirms a 45 mm HER2-positive invasive tumour and the sampled axillary node is metastatic. The breast target and proven node are durably marked, pretreatment clinical stage and imaging are recorded, and indicated distant staging shows no metastases.
- 2The oncology team confirms cardiac fitness and the relevant high-risk neoadjuvant eligibility. After the patient discusses benefits, toxicity and fertility implications, she starts the selected taxane-containing chemotherapy and trastuzumab-based HER2 treatment through the commissioned pathway.
- 3During treatment the lesion becomes much smaller and the patient has manageable fatigue. Serial review finds no clinical progression or cardiac deterioration requiring a change of plan. The team records the observed response but explains that reassuring imaging cannot establish a pathological complete response.
- 4The planned breast and axillary operations are completed and the marked targets are accounted for in the specimens. Pathology shows 12 mm of residual invasive HER2-positive disease in the breast. This is an observed incomplete invasive response, even though imaging had suggested a much smaller residual target.
- 5The multidisciplinary team retains the baseline stage and records the residual pathological findings separately. Because residual invasive disease follows the qualifying taxane and HER2-targeted neoadjuvant treatment, the team assesses adjuvant trastuzumab emtansine under TA632, alongside the indicated radiotherapy plan. The patient can explain why the postoperative pathology changes the next systemic decision.
02Triple-negative pathwayExplain benefit and toxicity of platinum-containing therapyA fit patient has high-risk non-metastatic triple-negative invasive cancer and the team recommends neoadjuvant chemotherapy.+
- 1Confirm phenotype, stage, fertility goals, germline testing eligibility and baseline full blood count and organ function.
- 2Offer a regimen containing platinum, taxane and anthracycline in line with NICE 2025, explaining improved survival, disease-free survival and pathological response evidence.
- 3Explain higher anaemia, neutropenia, thrombocytopenia and febrile-neutropenia risk and provide the oncology urgent-fever route.
- 4Monitor response and toxicity through treatment and use surgery to establish residual invasive disease before choosing adjuvant options.
03Postmenopausal ER-positive pathwayUse endocrine downstaging selectivelyA frail postmenopausal patient has ER-positive HER2-negative cancer that is difficult to conserve and has no definite chemotherapy indication.+
- 1Confirm strongly supported endocrine sensitivity, local extent and that delayed response will not compromise operability.
- 2Compare neoadjuvant endocrine therapy with surgery and chemotherapy, including slower shrinkage, menopausal and bone effects.
- 3Start the specialist-selected endocrine medicine and define examination and imaging review intervals before treatment begins.
- 4If the tumour fails to respond or progresses, return promptly to multidisciplinary planning rather than extending ineffective therapy indefinitely.
05Complications, monitoring and follow-upAdverse effects, response and longer-term review.
- Preserve baseline tumour and node measurements, photographs where relevant, clip locations, receptor results and cTNM in the record before the first dose.
- During treatment, monitor full blood count, organ function, infection, neuropathy and regimen-specific cardiac or immune toxicity through oncology protocols.
- At each response point, use the same clinical and imaging targets and trigger multidisciplinary review for progression, intolerance or lost operability.
- After surgery, record ypTNM and pathological response and connect residual disease explicitly to current adjuvant and radiotherapy pathways.
06Special situationsVariants, exceptions and circumstances that change the usual approach.
The clip survives response
A marker preserves the original malignant target when treatment leaves no palpable or visible lesion and helps pathology assess the correct bed.
Response is treatment information
Pathological complete response has prognostic meaning in some phenotypes, while residual disease can identify benefit from postoperative escalation.
Original extent still matters
Surgery and radiotherapy cannot be based only on the smallest post-treatment image because scattered residual cells and initial nodal burden remain relevant.
Endocrine response is slower
Neoadjuvant endocrine therapy can downstage selected postmenopausal ER-positive tumours but needs a longer, measured plan and an early failure route.
07Common pitfallsFrequent interpretation and management errors.
- 01
Starting systemic therapy before obtaining complete receptors, axillary evidence and target markers can make later surgery and pathology unreliable.
- 02
Using radiological disappearance as permission to omit surgery assumes a pathological response that imaging cannot prove.
- 03
Offering a platinum-containing triple-negative regimen without counselling about marrow toxicity prevents informed consent and safe fever action.
- 04
Continuing an ineffective endocrine neoadjuvant course without interval measurement can allow loss of operability.